Cargando…
Prevention of risks associated with inappropriate use/unnecessary consumption of medicines()
In the code of public health, misuse is defined as intentional and inappropriate use of a medicine or product, which is not in accordance with the terms of the marketing authorisation or the registration as well as with good practice recommendations. Very often this involves an individual or the int...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783759/ https://www.ncbi.nlm.nih.gov/pubmed/35078658 http://dx.doi.org/10.1016/j.therap.2022.01.003 |
_version_ | 1784638601121759232 |
---|---|
author | Cracowski, Jean-Luc Muller, Sophie Anglade, Isabelle Bonnefond, Gilles Bouhanick, Béatrice Bouquet, Sylvain Cabut, Sandrine Daynès, Pascale Denis, Bernard Durand, Dorothée Jonville-Béra, Annie-Pierre Lahouegue, Amir Léo, Magali Micallef, Joëlle Molimard, Mathieu Penfornis, Catherine Querol-Ferrer, Valérie |
author_facet | Cracowski, Jean-Luc Muller, Sophie Anglade, Isabelle Bonnefond, Gilles Bouhanick, Béatrice Bouquet, Sylvain Cabut, Sandrine Daynès, Pascale Denis, Bernard Durand, Dorothée Jonville-Béra, Annie-Pierre Lahouegue, Amir Léo, Magali Micallef, Joëlle Molimard, Mathieu Penfornis, Catherine Querol-Ferrer, Valérie |
author_sort | Cracowski, Jean-Luc |
collection | PubMed |
description | In the code of public health, misuse is defined as intentional and inappropriate use of a medicine or product, which is not in accordance with the terms of the marketing authorisation or the registration as well as with good practice recommendations. Very often this involves an individual or the interaction of several individuals including the patient, his/her carers, prescriber(s) and/or dispensers. Misuse is common; it is the source of medicinal adverse effects for which a significant part is avoidable. Medicines initially prescribed or dispensed in the context of their marketing authorization (MA) can also be the subject of primary dependency and misappropriation. Companies which develop medicines nationally make declarations to the ANSM (French National Agency for the Safety of Medicines and Health Products) and implement measures to limit non-compliant use of their products. Recently, the coronavirus disease-2019 (COVID-19) pandemic has highlighted the influence and societal impact of drug misuse. The finding of the existence of systemic misuse, the impossibility of proposing simple solutions leads us to propose two main areas for improved information and the training of users and health professionals in medicines in the context of multi-faceted interventions: prevention of misuse on the one hand and its identification and treatment on the other hand. |
format | Online Article Text |
id | pubmed-8783759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87837592022-01-24 Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() Cracowski, Jean-Luc Muller, Sophie Anglade, Isabelle Bonnefond, Gilles Bouhanick, Béatrice Bouquet, Sylvain Cabut, Sandrine Daynès, Pascale Denis, Bernard Durand, Dorothée Jonville-Béra, Annie-Pierre Lahouegue, Amir Léo, Magali Micallef, Joëlle Molimard, Mathieu Penfornis, Catherine Querol-Ferrer, Valérie Therapie Giens Workshops 2021/Health and economy In the code of public health, misuse is defined as intentional and inappropriate use of a medicine or product, which is not in accordance with the terms of the marketing authorisation or the registration as well as with good practice recommendations. Very often this involves an individual or the interaction of several individuals including the patient, his/her carers, prescriber(s) and/or dispensers. Misuse is common; it is the source of medicinal adverse effects for which a significant part is avoidable. Medicines initially prescribed or dispensed in the context of their marketing authorization (MA) can also be the subject of primary dependency and misappropriation. Companies which develop medicines nationally make declarations to the ANSM (French National Agency for the Safety of Medicines and Health Products) and implement measures to limit non-compliant use of their products. Recently, the coronavirus disease-2019 (COVID-19) pandemic has highlighted the influence and societal impact of drug misuse. The finding of the existence of systemic misuse, the impossibility of proposing simple solutions leads us to propose two main areas for improved information and the training of users and health professionals in medicines in the context of multi-faceted interventions: prevention of misuse on the one hand and its identification and treatment on the other hand. Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2022 2022-01-07 /pmc/articles/PMC8783759/ /pubmed/35078658 http://dx.doi.org/10.1016/j.therap.2022.01.003 Text en © 2022 Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Giens Workshops 2021/Health and economy Cracowski, Jean-Luc Muller, Sophie Anglade, Isabelle Bonnefond, Gilles Bouhanick, Béatrice Bouquet, Sylvain Cabut, Sandrine Daynès, Pascale Denis, Bernard Durand, Dorothée Jonville-Béra, Annie-Pierre Lahouegue, Amir Léo, Magali Micallef, Joëlle Molimard, Mathieu Penfornis, Catherine Querol-Ferrer, Valérie Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
title | Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
title_full | Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
title_fullStr | Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
title_full_unstemmed | Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
title_short | Prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
title_sort | prevention of risks associated with inappropriate use/unnecessary consumption of medicines() |
topic | Giens Workshops 2021/Health and economy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783759/ https://www.ncbi.nlm.nih.gov/pubmed/35078658 http://dx.doi.org/10.1016/j.therap.2022.01.003 |
work_keys_str_mv | AT cracowskijeanluc preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT mullersophie preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT angladeisabelle preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT bonnefondgilles preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT bouhanickbeatrice preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT bouquetsylvain preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT cabutsandrine preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT daynespascale preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT denisbernard preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT duranddorothee preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT jonvilleberaanniepierre preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT lahouegueamir preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT leomagali preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT micallefjoelle preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT molimardmathieu preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT penforniscatherine preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines AT querolferrervalerie preventionofrisksassociatedwithinappropriateuseunnecessaryconsumptionofmedicines |